文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

儿童脉络膜新生血管膜的纵向特征

Longitudinal Characteristics of Choroidal Neovascular Membrane in Pediatric Patients.
PubMed 文献 · Am J Ophthalmol · 2024-01-07

这项回顾性临床队列研究分析了2个中心2005至2022年25例儿童(30眼)的脉络膜新生血管膜(CNVM),发现最常见病因为特发性(48%)和炎症性(20%),多数为单侧(80%)、活动性(83.3%)和黄斑旁(46.7%)。25眼(83.3%)接受治疗,最常用一线治疗为玻璃体内注射抗血管内皮生长因子(抗VEGF)(92%),再治疗率52.2%,平均再治疗间隔237天,每眼平均总注射次数2.3次。随访平均56.46±42.51个月,末次随访时视力增益3行或15个ETDRS字母,未报告与治疗相关的眼部或全身并发症。

要点

  • 儿童CNVM最常见病因为特发性(48%)和炎症性(20%),多数为单侧(80%)。
  • 25眼(83.3%)接受治疗,最常用一线治疗为玻璃体内抗VEGF注射(92%)。
  • 再治疗率52.2%,平均再治疗间隔237天,每眼平均总注射次数2.3次。

核心结论

  • 儿童CNVM存在多种基础病因,最常为单侧;玻璃体内抗VEGF治疗可能有益,且不常需要频繁或长期给药;OCTA显示CNVM血管密度、血管长度密度及视网膜色素上皮脱离高度降低。

研究设计与样本

  • 回顾性临床队列研究,纳入2个中心2005至2022年的25例儿童(56%为女孩)共30眼,描述临床特征、影像学表现、治疗方案和结局。

主要发现

  • CNVM最常见病因为特发性(48%)和炎症性(20%);诊断时多数为单侧(80%)、活动性(83.3%)和黄斑旁(46.7%)。
  • 25眼(83.3%)来自21例患者(84%)接受治疗,最常用一线治疗为玻璃体内抗VEGF注射(92%),再治疗率52.2%,平均再治疗间隔237天,每眼平均总注射次数2.3次,52.2%的注射在诊所安全完成。
  • 末次随访时观察到3行或15个ETDRS字母的视力增益,平均随访时长56.46±42.51个月,未报告与治疗相关的眼部或全身并发症。
  • 16眼(64%)在初诊和末次随访时均有OCTA图像,显示CNVM血管密度、血管长度密度及视网膜色素上皮脱离高度降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the clinical and imaging characteristics, including optical coherence tomography angiography (OCTA), and treatment outcomes of choroidal neovascular membranes (CNVMs) in children. DESIGN: Retrospective clinical cohort study. METHODS: Thirty eyes from 25 children (56% girls) with CNVM from 2 centers were examined from 2005 to 2022. Clinical features, imaging findings, treatment regimens, and outcomes are described. RESULTS: The most common causes of CNVM were idiopathic (48%) and inflammatory (20%). At diagnosis, most CNVMs were unilateral (80%), active (83.3%), and juxtafoveal (46.7%). Twenty-five eyes (83.3%) of 21 patients (84%) were treated. The most common first-line treatment was intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) (92%), with a retreatment rate of 52.2% at an average of 237 days. The average number of total injections per eye was 2.3. Injections were safely administered in the clinic (52.2%). A gain of 3 lines or 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters was observed at final visit. The average duration of follow-up was 56.46 ± 42.51 months. No ocular or systemic complication related to treatment was reported. Sixteen eyes (64%) had OCTA images at both presentation and final visit, which showed a decrease in CNVM vessel density and vessel-length density, and in the height of retinal pigment epithelium detachment (RPED). CONCLUSIONS: There are a variety of underlying etiologies for pediatric CNVMs, which are most often unilateral. Treatment with intravitreal anti-VEGF can be beneficial and does not often require frequent or chronic dosing. OCTA demonstrated a decrease in the CNVM vessel density and vessel-length density as well as in the height of RPED.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hoyek S, Lu Y, Mukai S, et al. Longitudinal Characteristics of Choroidal Neovascular Membrane in Pediatric Patients. Am J Ophthalmol. 2024. PMID: 38195046. doi:10.1016/j.ajo.2024.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。